KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer

References

• Siegel RL , MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J. Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• NCCN . NCCN Clinical Practice Guidelines in oncology – prostate cancer, v1.2020. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Fizazi K , TranN, FeinLet al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Eng. J. Med.377(4), 352–360 (2017).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ , ChenYH, CarducciMet al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Eng. J. Med.373(8), 737–746 (2015).
   PubMed Web of Science ®Google Scholar
• Tamada S , IguchiT, KatoMet al. Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget9(97), 36966–36974 (2018).
   PubMedGoogle Scholar
• Gillessen S , AttardG, BeerTMet al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur. Urol.77(4), 508–547 (2020).
   PubMed Web of Science ®Google Scholar
• Tannock IF , de WitR, BerryWRet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Eng. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , TangenCM, HussainMHet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Eng. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Oudard S , FizaziK, SengelovLet al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized Phase III trial-FIRSTANA. J. Clin. Oncol.35(28), 3189–3197 (2017).
   PubMed Web of Science ®Google Scholar
• de Bono JS , SmithMR, SaadFet al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur. Urol.71(4), 656–664 (2017).
   PubMed Web of Science ®Google Scholar
• de Wit R , de BonoJ, SternbergCNet al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Eng. J. Med.381(26), 2506–2518 (2019).
   PubMed Web of Science ®Google Scholar
• Cornford P , BellmuntJ, BollaMet al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol.71(4), 630–642 (2017).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , VogelzangNJ, BudnikNet al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled Phase III trial. Lancet Oncol.16(4), 417–425 (2015).
   PubMed Web of Science ®Google Scholar
• Araujo JC , TrudelGC, SaadFet al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized Phase III READY trial. J. Clin. Oncol.31(Suppl. 6), (2013).
   PubMedGoogle Scholar
• Fizazi K , HiganoCS, NelsonJBet al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol.31(14), 1740–1747 (2013).
   PubMed Web of Science ®Google Scholar
• Scher HI , JiaX, ChiKet al. Randomized, open-label Phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol.29(16), 2191–2198 (2011).
   PubMed Web of Science ®Google Scholar
• Tannock IF , FizaziK, IvanovSet al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a Phase III, double-blind randomised trial. Lancet Oncol.14(8), 760–768 (2013).
   PubMed Web of Science ®Google Scholar
• Chi KN , HiganoCS, BlumensteinBet al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a Phase III, multicentre, open-label, randomised trial. Lancet Oncol.18(4), 473–485 (2017).
   PubMed Web of Science ®Google Scholar
• Small E , DemkowT, GerritsenGRet al. A Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). J. Clin. Oncol.27(Suppl. 15S) (2009).
   Google Scholar
• Quinn DI , TangenCM, HussainMet al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised Phase III trial. Lancet Oncol.14(9), 893–900 (2013).
   PubMed Web of Science ®Google Scholar
• Crabb SJ , GriffithsGO, MarwoodEet al. ProCAID: a randomized double-blind Phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol.38(Suppl. 15), 5520 (2020).
   Web of Science ®Google Scholar
• Madan RA , KarzaiFH, AlHarthy Met al. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU Int.127(4), 345–444 (2020).
   Web of Science ®Google Scholar
• Cabel L , LoirE, GravisGet al. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. J. Immunother. Cancer5, 31 (2017).
   PubMed Web of Science ®Google Scholar
• Fizazi K , DrakeCG, BeerTMet al. Final analysis of the ipilimumab versus placebo following radiotherapy Phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur. Urol.78(6), 822–830 (2020).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Eng. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Iwai Y , IshidaM, TanakaY, OkazakiT, HonjoT, MinatoN. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19), 12293–12297 (2002).
   PubMed Web of Science ®Google Scholar
• Gevensleben H , DietrichD, GolletzCet al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin. Cancer Res.22(8), 1969–1977 (2016).
   PubMed Web of Science ®Google Scholar
• Haffner MC , GunerG, TaheriDet al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am. J. Pathol.188(6), 1478–1485 (2018).
   PubMed Web of Science ®Google Scholar
• Bishop JL , SioA, AngelesAet al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget6(1), 234–242 (2015).
   PubMedGoogle Scholar
• Fizazi K , GonzalezMella P, CastellanoDet al. Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD. Ann. Oncol.30(Suppl. 5), v885–v886 (2019).
   Google Scholar
• Agarwal N , LoriotY, McGregorBAet al. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of Cohort 6 of the COSMIC-021 study. J. Clin. Oncol.38(Suppl. 6), 139–139 (2020).
   Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp . KEYTRUDA® (pembrolizumab) for injection, for intravenous use. Merck Sharp & Dohme, Corp, NJ, USA, 83 (2020).
   Google Scholar
• Hansen AR , MassardC, OttPAet al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol.29(8), 1807–1813 (2018).
   PubMed Web of Science ®Google Scholar
• Antonarakis ES , PiulatsJM, Gross-GoupilMet al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label Phase II KEYNOTE-199 study. J. Clin. Oncol.38(5), 395–405 (2020).
   PubMed Web of Science ®Google Scholar
• Kolinsky MP , GravisG, MoureyMet al. KEYNOTE-365 cohort B updated results: pembrolizumab plus docetaxel and prednisone in abiraterone or enzalutamide-pretreated patients with metastatic castrate-resistant prostate cancer. J. Clin. Oncol.38(Suppl. 6), Abstr. 103 (2020).
   Web of Science ®Google Scholar
• Drake CG , SaadF, ClarkWRet al. 690TiP a Phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX). Ann. Oncol.31, S546 (2020).
   Google Scholar
• Morris MJ , MolinaA, SmallEJet al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J. Clin. Oncol.33(12), 1356–1363 (2015).
   PubMed Web of Science ®Google Scholar
• Scher HI , MorrisMJ, StadlerWMet al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J. Clin. Oncol.34(12), 1402–1418 (2016).
   PubMed Web of Science ®Google Scholar